Developing LNP formulations can be both time-consuming and expensive. Participants will explore the critical role of ionizable lipids in LNP formulations and gain insights into our capabilities for customized LNP formulation development for novel therapeutic modalities. The session will cover essential topics, including screening, optimization, analytical characterization, in vivo testing, and scale-up strategies for LNPs. This comprehensive approach emphasizes the significance of LNPs in advancing therapeutic modalities and improving patient lives.
In this webinar, you will discover and learn about:
- demonstrated efficacy of multiple lipid libraries through case studies in the preclinical phase
- the impact of screening versatile libraries containing carefully selected lipids for various applications, payloads and target tissues
- the benefits of flexible manufacturing approaches for LNP formulation scale-up
Speaker
Johanna Simon, Ph.D.
MilliporeSigma
Principial Scientist
Johanna Simon, Ph.D., is a principal scientist in the Early Formulation Screening Service in Life Science Services at MilliporeSigma. Her work focuses on the preclinical formulation development of custom lipid nanoparticles for nucleic acid modalities.
After receiving her Ph.D. in Chemistry, Johanna has continued her scientific career as a postdoctoral researcher with a focus on developing antibody-functionalized nanoparticles for targeted drug delivery in vivo. Johanna has authored 50+ peer-reviewed articles in leading journals in the field of drug delivery sciences.
Pharma and biopharma manufacturing
- Pharma and biopharma manufacturing
Duration:1h
Language:English
Session 1:presented June 5, 2025
To continue reading please sign in or create an account.
Don't Have An Account?